Account

Sign in to access your account and subscription

Product-By-Process Claim Construction: Conflict in Federal Circuit Precedent Remains Unresolved

Construing claims that use the process by which a product is created to define the invention ' that is, product-by-process claims ' was not made any easier by the Federal Circuit's recent decision in <i>SmithKline Beecham Corp. v. Apotex Corp.</i>, 439 F.3d 1312 (Fed. Cir. 2006). The Federal Circuit again declined to resolve the long-standing conflict between two decisions ' the 1991 decision in <i>Scripps Clinic &amp; Res. Foun. v. Genentech Corp.</i>, 927 F.2d 1565 (Fed. Cir. 1991), which held that product-by-process claims <i>should not</i> be limited by the process steps in the claims, (<i>i.e.</i>, such claims cover an identical end-product regardless of the steps used) and the 1992 decision in <i>Atlantic Thermoplastics Co. v. Faytex Corp.</i>, 970 F.2d 834 (Fed. Cir. 1992), which held that product-by-process claims <i>should</i> be construed to only cover the end-product if produced by the specifically claimed process steps. As explained below, this state of affairs warrants that patent applicants and litigants stay tuned to the case law and adjust their respective claim drafting and analysis strategies accordingly.

23 minute read May 30, 2007 at 12:18 PM
By
Jonathan S. Caplan and Mary W. Richardson
Product-By-Process Claim Construction: Conflict in Federal Circuit Precedent Remains Unresolved

Construing claims that use the process by which a product is created to define the invention ' that is, product-by-process claims ' was not made any easier by the Federal Circuit's recent decision in SmithKline Beecham Corp. v.

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The combination of increasing operating costs and uncertain government reimbursement funding continues to place health care providers under financial pressure, and in many cases, financial distress. Given the importance of Medicare/Medicaid funding of claims under provider agreements with the federal government, how courts interpret and apply the interplay between the Bankruptcy Code and Medicare Program Act determines the disposition of hundreds of millions of dollars of claims for reimbursement that support the health care system.

April 30, 2026

As AI becomes embedded in everyday business and legal operations, organizations are confronting a new expectation: simply disclosing AI use is no longer enough. A critical shift is taking place in the legal industry: transparency is no longer just about disclosure; it’s about comprehension.

April 30, 2026